Welcome to our dedicated page for Manhattan Scientifics news (Ticker: MHTX), a resource for investors and traders seeking the latest updates and insights on Manhattan Scientifics stock.
Manhattan Scientifics Inc. (MHTX) drives innovation in nanomedicine through cutting-edge technological solutions. This comprehensive news hub provides investors and industry observers with essential updates on corporate developments, research breakthroughs, and strategic partnerships shaping the future of healthcare technology.
Access timely updates including financial disclosures, patent filings, clinical trial progress, and executive leadership changes. Our curated collection ensures you stay informed about MHTX's advancements in developing sustainable nanomedicine applications and disruptive healthcare solutions.
Key coverage areas include scientific collaborations, regulatory milestones, and technology commercialization efforts. Bookmark this page for direct access to official press releases and objective reporting on Manhattan Scientifics' journey to transform medical innovation.
Manhattan Scientifics Inc. (OTCQB: MHTX) announced positive early results from the human study of Imagion Biosystems' cancer diagnostic technology. Following the announcement, shares of Imagion Biosystems (IBX.AX) surged by 46%, reaching 71 million in trading volume. Manhattan Scientifics owns over 50 million shares of Imagion, indicating a significant investment in the company’s future. The press release highlights the innovative diagnostic technology aimed at early cancer detection, emphasizing its non-radioactive and super-sensitive nature.
Manhattan Scientifics Inc. (OTC: QB) holds over 50 million shares of Imagion Biosystems (IBX.AX), focused on developing advanced non-radioactive cancer imaging technology. A televised interview with Imagion's CEO, Bob Proulx, is highlighted, discussing their innovative diagnostic solutions aimed at early cancer detection. The press release emphasizes the partnership and technology transfer efforts with Los Alamos and Sandia National Laboratories in New Mexico. The company warns that investments are high risk, with future results uncertain, stressing forward-looking statements are not guarantees of performance.
Manhattan Scientifics Inc. (OTCQB: MHTX) has invested $30 million and committed to a 10-year effort to commercialize a non-invasive cancer diagnostic in partnership with MD Anderson Cancer Center. The company is currently awaiting regulatory approval to commence human trials. The CEO expressed intentions to enhance shareholder value, despite the company's market cap fluctuations, which have seen a peak near $1 billion and a low of $17 million.
Manhattan Scientifics Inc. (OTCQB: MHTX) announced year-end updates on its Nano-Medicine Cancer and Nano-Medical Metal Alloy initiatives. The company owns over 50 million shares of Imagion Biosystems Ltd. (ASX: IBX), which has made significant progress, including establishing clinical trials and increasing cash reserves to $10.13 million. MHTX also anticipates royalties from its licensed nano-metal technology for medical prosthetics, expecting to start earning in 2021. Management emphasizes low overhead and a strong commitment to the company's growth.
FAQ
What is the current stock price of Manhattan Scientifics (MHTX)?
What is the market cap of Manhattan Scientifics (MHTX)?
